Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 15/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 12/20 | 0.49 |
| ▸ | PIM1 | P11309 | 10/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13027707 | 1.00 | PIM2 (0.49) | PIM2PIM3PIM1CHEK1ATR | |
| SCHEMBL13027740 | 0.93 | PIM2 (0.59) | PIM2PIM3PIM1ATR | |
| SCHEMBL13027725 | 0.93 | PIM2 (0.59) | PIM2PIM3PIM1ATR | |
| SCHEMBL13027504 | 0.86 | PIM3 (0.50) | PIM2PIM3PIM1CHEK1MAP4K1 | |
| SCHEMBL13027496 | 0.86 | PIM3 (0.50) | PIM2PIM3PIM1CHEK1MAP4K1 | |
| SCHEMBL13156781 | 0.83 | CHEK1 (0.70) | PIM2PIM3PIM1CHEK1MAP4K1 | |
| SCHEMBL16519608 | 0.83 | CHEK1 (0.70) | PIM2PIM3PIM1CHEK1MAP4K1 | |
| SCHEMBL13156785 | 0.83 | CHEK1 (0.70) | PIM2PIM3PIM1CHEK1MAP4K1 | |
| SCHEMBL11924095 | 0.81 | PIM2 (0.48) | PIM2PIM3PIM1CHEK1ATR | |
| SCHEMBL11924017 | 0.81 | PIM2 (0.47) | PIM2PIM3PIM1CHEK1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009014637-A2 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MTOR, CDK1, MAP3K8 | PIM2 890/4885PIM3 929/4885PIM1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.